About Tumor necrosis factor receptor superfamily member 6
Tumor necrosis factor receptor superfamily member 6 (FAS) is a protein
from Homo sapiens identified by UniProt accession
P25445, 335 residues long.
MolForge cross-references it against 0 known binders and
956 disease associations.
Target properties
| Protein name | Tumor necrosis factor receptor superfamily member 6 |
|---|
| UniProt accession | P25445 |
|---|
| Gene | FAS |
|---|
| Organism | Homo sapiens |
|---|
| Length | 335 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Disease associations (956)
Diseases linked to this target (Open Targets).
- autoimmune lymphoproliferative syndrome · score 0.73
- lymphoma · score 0.51
- neurodegenerative disease · score 0.48
- cutaneous melanoma · score 0.42
- diffuse large B-cell lymphoma · score 0.42
- genetic disorder · score 0.40
- Hashimoto's thyroiditis · score 0.39
- adult T-cell leukemia/lymphoma · score 0.37
- marginal zone B-cell lymphoma · score 0.37
- lymphoid neoplasm · score 0.37
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-P25445-F1 | alphafold | PREDICTED | 77.88 | — |
Amino-acid sequence (335 residues)
MLGIWTLLPL VLTSVARLSS KSVNAQVTDI NSKGLELRKT VTTVETQNLE GLHHDGQFCH KPCPPGERKA RDCTVNGDEP DCVPCQEGKE YTDKAHFSSK CRRCRLCDEG HGLEVEINCT RTQNTKCRCK PNFFCNSTVC EHCDPCTKCE HGIIKECTLT SNTKCKEEGS RSNLGWLCLL LLPIPLIVWV KRKEVQKTCR KHRKENQGSH ESPTLNPETV AINLSDVDLS KYITTIAGVM TLSQVKGFVR KNGVNEAKID EIKNDNVQDT AEQKVQLLRN WHQLHGKKEA YDTLIKDLKK ANLCTLAEKI QTIILKDITS DSENSNFRNE IQSLV
Explore Tumor necrosis factor receptor superfamily member 6 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets